Since CD4+CD25− T-cells represent terminally differentiated (effector) T-cells, we postulate that chronic antigenic exposure and prolonged inflammation may contribute to the expansion of this subset in patients with MS. The gene discussed is CD4; the disease is myeloid sarcoma.